Stock Scorer

Autonomix Medical, Inc. (AMIX)

Autonomix Medical, Inc. reported revenue of 0 USD for the quarter ending 30 June 2026.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 0 —
Operating Income Q2 '26 · ending 30 June 2026 -2.8M —
Net Income Q2 '26 · ending 30 June 2026 -2.7M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -3.5M —
Free Cash Flow Q1 '26 · ending 31 March 2026 -2.9M —
Shares Outstanding Q2 '26 · ending 30 June 2026 543.7K -70.6%
EPS Q4 '25 · ending 31 December 2025 -25.17 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20262026-03-31 0-17M-16.7M-12.3M
20252025-03-31 0-11.6M-11.4M-8.3M
20242024-03-31 0-12M-15.4M-6.6M
20232023-03-31 0-2M-2M-1.9M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q1 '272026-06-300
Q4 '262026-03-310
Q3 '262025-12-310
Q2 '262025-09-300
Q1 '262025-06-300
Q4 '252025-03-310
Q3 '252024-12-310
Q2 '252024-09-300
Q1 '252024-06-300
Q4 '242024-03-310
Q3 '242023-12-310
Q2 '242023-09-300
Q1 '242023-06-300

Operating Income Quarterly

PeriodEndingOperating Income
Q1 '272026-06-30-2.8M
Q4 '262026-03-31-2.7M
Q3 '262025-12-31-3.3M
Q2 '262025-09-30-7.5M
Q1 '262025-06-30-3.4M
Q4 '252025-03-31-3.3M
Q3 '252024-12-31-2.7M
Q2 '252024-09-30-2.8M
Q1 '252024-06-30-2.8M
Q4 '242024-03-31-2.4M
Q3 '242023-12-31-2.9M
Q2 '242023-09-30-5.8M
Q1 '242023-06-30-871K
Q4 '232023-03-31-657K
Q3 '232022-12-31-544K

Net Income Quarterly

PeriodEndingNet Income
Q1 '272026-06-30-2.7M
Q4 '262026-03-31-2.7M
Q3 '262025-12-31-3.3M
Q2 '262025-09-30-7.5M
Q1 '262025-06-30-3.3M
Q4 '252025-03-31-11.4M
Q3 '252024-12-31-2.7M
Q2 '252024-09-30-2.8M
Q1 '252024-06-30-2.7M
Q4 '242024-03-31-15.4M
Q3 '242023-12-31-3.1M
Q2 '242023-09-30-6M
Q1 '242023-06-30-865K
Q4 '232023-03-31-657K
Q3 '232022-12-31-544K
Q2 '232022-09-30-448K
Q1 '232022-06-30-341K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q1 '272026-06-30-3.5M
Q4 '262026-03-31-2.9M
Q3 '262025-12-31-3M
Q2 '262025-09-30-3.8M
Q1 '262025-06-30-2.6M
Q4 '252025-03-31-8.3M
Q3 '252024-12-31-2.3M
Q2 '252024-09-30-1.6M
Q1 '252024-06-30-1.9M
Q4 '242024-03-31-6.6M
Q3 '242023-12-31-2.6M
Q2 '242023-09-30-1.1M
Q1 '242023-06-30-661K
Q4 '232023-03-31-620K

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '262026-03-31-2.9M
Q3 '262025-12-31-3M
Q2 '262025-09-30-3.8M
Q1 '262025-06-30-2.6M
Q4 '252025-03-31-8.3M
Q3 '252024-12-31-2.3M
Q2 '252024-09-30-1.6M
Q1 '252024-06-30-1.9M
Q4 '242024-03-31-6.7M
Q3 '242023-12-31-2.6M
Q2 '242023-09-30-1.1M
Q1 '242023-06-30-661K
Q4 '232023-03-31-620K

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q1 '272026-06-30543.7K
Q3 '262025-12-319M
Q2 '262025-09-305.4M
Q1 '262025-06-30147.1K
Q3 '252024-12-311.9M
Q2 '252024-09-301.2M
Q1 '252024-06-301.2M
Q3 '242023-12-3113.8M
Q2 '242023-09-30687.8K
Q1 '242023-06-3012.9M
Q3 '232022-12-3112M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q3 '262025-12-31-25.17
Q2 '262025-09-30-26.27
Q1 '262025-06-30-27.16
Q4 '252025-03-31-6.67
Q3 '252024-12-31-10.73
Q2 '252024-09-30-9.50
Q1 '252024-06-30-16.01
Q4 '242024-03-31-13.88
Q3 '242023-12-31-9.14
Q2 '242023-09-30-8.96